Blog

(*) Subject to modifications. Press releases will be published after market close.

Upcoming events Theradiag will attend:

• January 21-24, 2020: 10^th Congress of Human and Medical Genetics, Tours, France
• January 24, 2020: 13^th National Conference of IBD (Chronic Inflammatory Bowel Diseases), Paris
• February 12-15, 2020: 15^th ECCO (European Crohn’s and Colitis Organisation) Congress, Vienna, Austria
• March 5-6, 2020: Biomed-J 2020 (Young Medical Biologists’ Association), Paris
• March 6-7, 2020: GETAID Seminar (Therapeutic Study Group for Inflammatory Digestive Tract Diseases), Paris
• March 26-29, 2020: JFHOD congress (Hepato-gastroenterology and Digestive Oncology), Paris.

About Theradiag

Capitalizing on its expertise in the distribution, development and manufacturing of in vitro diagnostic tests, Theradiag innovates and develops theranostics tests (combining treatment and diagnosis) that measure the efficiency of biotherapies in the treatment of autoimmune diseases and cancer. Theradiag is thus participating in the development of customized treatment, which favors the individualization of treatments, the evaluation of their efficacy and the prevention of drug resistance. Theradiag notably markets the Lisa Tracker® range (CE marked), which is a comprehensive multiparameter theranostic solution for patients with autoimmune diseases treated with biotherapies. The Company is based in Marne-la-Vallée, near Paris, and has over 60 employees.